Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...

Hims & Hers Health (HIMS) stock rocketed higher today after the telehealth platform operator announced plans to introduce ...

By acquiring Sigmund NJ LLC, known as Trybe Labs, Hims & Hers will be able "to support at-home blood draws and more ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.

Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab ...